Published in J Proteomics on January 20, 2009
Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer. Nat Commun (2016) 1.39
Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. Mol Cell Proteomics (2012) 1.08
In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine. Proteomics (2013) 1.06
miR-888 is an expressed prostatic secretions-derived microRNA that promotes prostate cell growth and migration. Cell Cycle (2013) 1.03
Identification of prostate cancer biomarkers in urinary exosomes. Oncotarget (2015) 1.00
Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine. J Proteome Res (2012) 0.97
In-depth proteomic analyses of direct expressed prostatic secretions. J Proteome Res (2010) 0.97
Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology. AAPS J (2010) 0.93
iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer. PLoS One (2012) 0.89
Increased bisecting N-acetylglucosamine and decreased branched chain glycans of N-linked glycoproteins in expressed prostatic secretions associated with prostate cancer progression. Proteomics Clin Appl (2013) 0.87
Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers. Nat Rev Urol (2013) 0.87
The application of SELDI-TOF-MS in clinical diagnosis of cancers. J Biomed Biotechnol (2011) 0.85
The present and future of prostate cancer urine biomarkers. Int J Mol Sci (2013) 0.85
Advances in urinary protein biomarkers for urogenital and non-urogenital pathologies. Biochem Med (Zagreb) (2015) 0.83
Glycoprotein fucosylation is increased in seminal plasma of subfertile men. Asian J Androl (2015) 0.83
Urinary proteomics and metabolomics studies to monitor bladder health and urological diseases. BMC Urol (2016) 0.78
Dysregulated expression of cell surface glycoprotein CDCP1 in prostate cancer. Oncotarget (2015) 0.75
The C-terminal fragment of prostate-specific antigen, a 2331 Da peptide, as a new urinary pathognomonic biomarker candidate for diagnosing prostate cancer. PLoS One (2014) 0.75
Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery. Oncotarget (2017) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA (1998) 21.31
20-year outcomes following conservative management of clinically localized prostate cancer. JAMA (2005) 12.25
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst (2003) 11.27
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2006) 9.91
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst (2002) 9.45
A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA (1995) 8.60
Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med (1991) 6.94
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA (2005) 6.50
Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med (1987) 6.41
Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol (1968) 5.98
Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA (1993) 5.77
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst (2007) 5.69
Results of conservative management of clinically localized prostate cancer. N Engl J Med (1994) 5.04
AN " ACID " PHOSPHATASE OCCURRING IN THE SERUM OF PATIENTS WITH METASTASIZING CARCINOMA OF THE PROSTATE GLAND. J Clin Invest (1938) 5.00
The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol (2006) 3.79
Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med (2008) 3.73
A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res (2008) 3.35
Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol (2006) 3.09
PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol (2008) 2.63
Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res (2007) 2.63
Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res (2007) 2.60
Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med (2001) 2.49
APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem (2006) 2.39
N-Glycans in cancer progression. Glycobiology (2008) 2.35
PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology (2007) 2.14
Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL. Can Urol Assoc J (2007) 2.04
The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions. Prostate (2008) 2.02
Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol (2007) 1.95
Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA (2000) 1.89
DD3PCA3 RNA analysis in urine--a new perspective for detecting prostate cancer. Eur Urol (2004) 1.89
Large-scale and high-confidence proteomic analysis of human seminal plasma. Genome Biol (2006) 1.84
Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer. Urology (1997) 1.79
Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst (1998) 1.74
The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res (2007) 1.68
Leukocytes and bacteria in men with chronic prostatitis/chronic pelvic pain syndrome compared to asymptomatic controls. J Urol (2003) 1.66
The GlycanBuilder: a fast, intuitive and flexible software tool for building and displaying glycan structures. Source Code Biol Med (2007) 1.61
[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol (2008) 1.47
Cell surface glycoconjugates as onco-differentiation markers in hematopoietic cells. Biochim Biophys Acta (1985) 1.40
The ten-year rule revisited: accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer. Urology (2002) 1.32
Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clin Cancer Res (2004) 1.19
Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology (2007) 1.15
Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation. Prostate (2008) 1.10
Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. Clin Cancer Res (2007) 1.02
Molecular PCA3 diagnostics on prostatic fluid. Prostate (2007) 1.01
Osteoporosis and fractures after androgen deprivation initiation for prostate cancer. Can J Urol (2007) 0.96
Glycosylation of urinary prostate-specific antigen in benign hyperplasia and cancer: assessment by lectin-binding patterns. Clin Biochem (2005) 0.95
Current age and race adjusted prostate specific antigen threshold values delay diagnosis of high grade prostate cancer. J Urol (2007) 0.95
Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection. J Urol (1998) 0.95
State-of-the-art staging in prostate cancer. BJU Int (2001) 0.93
Amidolytic activity of prostatic acid phosphatase on human semenogelins and semenogelin-derived synthetic substrates. Eur J Biochem (2002) 0.92
Influence of digital rectal massage on urinary prostate-specific antigen: interest for the detection of local recurrence after radical prostatectomy. Prostate (1998) 0.92
Urinary prostate specific antigen levels: role in monitoring the response of prostate cancer to therapy. J Urol (1992) 0.92
The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC). Prostate (2007) 0.90
Urinary prostate specific antigen levels after radical prostatectomy. J Urol (1994) 0.87
Proteomics cataloging analysis of human expressed prostatic secretions reveals rich source of biomarker candidates. Proteomics Clin Appl (2008) 0.87
The clinical usefulness of percent free-PSA. Urology (1996) 0.85
Defining high risk prostate cancer--where do we set the bar? A translational science approach to risk stratification. J Urol (2006) 0.84
Prostate-specific antigen: update 1997. J Int Fed Clin Chem (1997) 0.83
The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases. J Urol (1998) 0.82
Thiophilic interaction chromatography facilitates detection of various molecular complexes of prostate-specific antigen in biological fluids. Prostate (2002) 0.82
Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. Urology (2001) 0.81
Combined prostate-specific antigen density and biopsy features to predict "clinically insignificant" prostate cancer. Urology (2008) 0.80
Comparison of expressed prostatic secretions with urine after prostatic massage--a means to diagnose chronic prostatitis/inflammatory chronic pelvic pain syndrome. Urology (2000) 0.79
The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate. J Urol (2006) 0.79
Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res (2002) 7.11
Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol (2003) 4.28
Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancer. J Urol (2010) 3.87
Enhancement of sensitivity and resolution of surface-enhanced laser desorption/ionization time-of-flight mass spectrometric records for serum peptides using time-series analysis techniques. Clin Chem (2004) 3.28
Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem (2002) 3.05
Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl (2007) 2.84
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem (2007) 2.38
Using preoperative albumin levels as a surrogate marker for outcomes after radical cystectomy for bladder cancer. Urology (2013) 2.25
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem (2007) 2.23
Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann Surg Oncol (2004) 1.63
Imaging mass spectrometry of a specific fragment of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 2 discriminates cancer from uninvolved prostate tissue. Clin Cancer Res (2009) 1.60
Human LINE-1 retrotransposon induces DNA damage and apoptosis in cancer cells. Cancer Cell Int (2006) 1.59
Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med (2010) 1.59
the need for review and understanding of SELDI/MALDI mass spectroscopy data prior to analysis. Cancer Inform (2005) 1.58
Restriction of virus infection but not catalytic dNTPase activity is regulated by phosphorylation of SAMHD1. J Virol (2013) 1.58
Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers. Mol Cell Proteomics (2006) 1.56
SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology (2005) 1.55
Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res (2002) 1.51
Tissue imaging using nanospray desorption electrospray ionization mass spectrometry. Anal Chem (2011) 1.50
Human T-cell leukemia virus-I tax oncoprotein functionally targets a subnuclear complex involved in cellular DNA damage-response. J Biol Chem (2003) 1.33
A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer (2003) 1.33
Computational protein biomarker prediction: a case study for prostate cancer. BMC Bioinformatics (2004) 1.31
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem (2008) 1.31
Staphylococcus aureus clumping factor A binds to complement regulator factor I and increases factor I cleavage of C3b. J Infect Dis (2008) 1.30
Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin Cancer Res (2005) 1.30
Identification of patients with head and neck cancer using serum protein profiles. Arch Otolaryngol Head Neck Surg (2004) 1.28
PDZ binding motif of HTLV-1 Tax promotes virus-mediated T-cell proliferation in vitro and persistence in vivo. Blood (2005) 1.19
Serum protein profiles to identify head and neck cancer. Clin Cancer Res (2004) 1.18
HTLV-1 Tax oncoprotein subverts the cellular DNA damage response via binding to DNA-dependent protein kinase. J Biol Chem (2008) 1.18
Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer. Dis Markers (2004) 1.18
Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology (2003) 1.15
Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids. J Proteome Res (2009) 1.13
Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer (2004) 1.12
Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples. Laryngoscope (2008) 1.10
Targeted identification of metastasis-associated cell-surface sialoglycoproteins in prostate cancer. Mol Cell Proteomics (2011) 1.09
Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. Mol Cell Proteomics (2012) 1.08
Retrotransposition-Competent Human LINE-1 Induces Apoptosis in Cancer Cells With Intact p53. J Biomed Biotechnol (2004) 1.08
Interaction of retroviral Tax oncoproteins with tristetraprolin and regulation of tumor necrosis factor-alpha expression. J Natl Cancer Inst (2003) 1.08
Comparative proteomic analysis of de-N-glycosylated serum from hepatitis B carriers reveals polypeptides that correlate with disease status. Proteomics (2004) 1.06
Site-specific phosphorylation differentiates active from inactive forms of the human T-cell leukemia virus type 1 Tax oncoprotein. J Biol Chem (2006) 1.05
Interaction domains of the UL16 and UL21 tegument proteins of herpes simplex virus. J Virol (2009) 1.04
The Sumo-targeted ubiquitin ligase RNF4 regulates the localization and function of the HTLV-1 oncoprotein Tax. Blood (2011) 1.04
Interlaboratory study on differential analysis of protein glycosylation by mass spectrometry: the ABRF glycoprotein research multi-institutional study 2012. Mol Cell Proteomics (2013) 1.03
SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. Dis Markers (2004) 1.03
Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients. J Am Coll Surg (2009) 1.01
Human T-cell leukemia virus type 1 Tax oncoprotein prevents DNA damage-induced chromatin egress of hyperphosphorylated Chk2. J Biol Chem (2007) 1.00
The HTLV-1 tax oncoprotein attenuates DNA damage induced G1 arrest and enhances apoptosis in p53 null cells. Virology (2003) 0.99
MALDI tissue imaging: from biomarker discovery to clinical applications. Anal Bioanal Chem (2011) 0.98
Staphylococcus aureus surface protein SdrE binds complement regulator factor H as an immune evasion tactic. PLoS One (2012) 0.97
In-depth proteomic analyses of direct expressed prostatic secretions. J Proteome Res (2010) 0.97
Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine. J Proteome Res (2012) 0.97
Functional and physical interaction between the mismatch repair and FA-BRCA pathways. Hum Mol Genet (2011) 0.97
Resampling and deconvolution of linear time-of-flight records for enhanced protein profiling. Rapid Commun Mass Spectrom (2006) 0.96
Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-κB-dependent autophagy. J Virol (2013) 0.95
Serum biomarkers to differentiate benign and malignant mammographic lesions. J Am Coll Surg (2007) 0.95
Signal detection in high-resolution mass spectrometry data. J Proteome Res (2008) 0.95
Potent inhibition of the classical pathway of complement by a novel C1q-binding peptide derived from the human astrovirus coat protein. Mol Immunol (2010) 0.95
The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology. Urol Oncol (2004) 0.95
Direct and specific binding of the UL16 tegument protein of herpes simplex virus to the cytoplasmic tail of glycoprotein E. J Virol (2011) 0.94
The role of telemedicine in the management of the pregnancy complicated by diabetes. Curr Diab Rep (2013) 0.93
On-tissue identification of insulin: in situ reduction coupled with mass spectrometry imaging. Proteomics Clin Appl (2011) 0.93
Requirements for protein phosphorylation and the kinase activity of polo-like kinase 1 (Plk1) for the kinetochore function of mitotic arrest deficiency protein 1 (Mad1). J Biol Chem (2008) 0.91
Hyperglycemic conditions inhibit C3-mediated immunologic control of Staphylococcus aureus. J Transl Med (2012) 0.90
Serum, salivary and tissue proteomics for discovery of biomarkers for head and neck cancers. Expert Rev Mol Diagn (2005) 0.90
The viral oncoprotein tax sequesters DNA damage response factors by tethering MDC1 to chromatin. J Biol Chem (2010) 0.88
Mining the low molecular weight proteome of blood. Proteomics Clin Appl (2007) 0.88
Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life. J Endourol (2007) 0.87
Single center experience with percutaneous and laparoscopic cryoablation of small renal masses. J Endourol (2009) 0.87
Dimerization and a novel Tax speckled structure localization signal are required for Tax nuclear localization. J Virol (2009) 0.87
Interdependent phosphorylation within the kinase domain T-loop Regulates CHK2 activity. J Biol Chem (2010) 0.86
MALDI/SELDI protein profiling of serum for the identification of cancer biomarkers. Methods Mol Biol (2008) 0.86
Precision enhancement of MALDI-TOF MS using high resolution peak detection and label-free alignment. Proteomics (2008) 0.86
The identification of serum biomarkers of high-let radiation exposure and biological sequelae. Health Phys (2010) 0.86
Nuclear trafficking of the human cytomegalovirus pp71 (ppUL82) tegument protein. Virology (2008) 0.86